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© 2012 The Japan Society of Histochemistry and The TRK-fused gene (TFG in human, Tfg in rat) was originally identified in human papillary
thyroid cancer as a chimeric form of the NTRK1 gene. It was since reported that the gene
product (TFG) plays a role in regulating phosphotyrosine-specific phosphatase-1 activity. As
shown in the accompanying paper, we produced an antibody to rat TFG and used it to
localize TFG to selected neurons in specific regions. In the present study, we mapped the
TFG-positive neurons in the brainstem, cerebellum, and spinal cord of rats. In the brainstem,
neurons intensely positive for TFG were distributed in the raphe nuclei, the gigantocellular
reticular nucleus, the reticulotegmental nucleus of the pons, and some cranial nerve nuclei
such as the trigeminal nuclei, the vestibulocochlear nuclei, and the dorsal motor nucleus of
the vagus. Purkinje cells in the cerebellum and motor neurons in the spinal anterior horn
were also positive for TFG. These results provide fundamental data for studying the functions
of TFG in the brain.
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I. Introduction
The TRK-fused gene (TFG in human, Tfg in rat) was
first identified in human papillary thyroid carcinoma as a
fusion partner of the NTRK1 gene [5], which encodes a
tyrosine kinase receptor for nerve growth factor [9, 10].
TFG was subsequently found as an oncogenic fusion gene
in various cancers, including anaplastic large cell lymphoma
[6], myxoid chondrosarcoma [7], and atypical myeloprolif-
erative neoplasms [3]. Recently, the gene product, TFG, was
implicated in regulating cargo export at the endoplasmic
reticulum [23].
Despite the TFG gene being expressed across several
cancerous and normal tissues [13, 14, 20], the function of
TFG protein remains unclear. In 2005, Roccato et al. [21]
reported that TFG protein interacts with and negatively
regulates the SH2 domain-containing phosphotyrosine-
specific phosphatase-1 (SHP-1), which is expressed in the
hematopoietic system [19, 24], epithelial cells [19], and the
nervous system [8, 12]. Therefore, TFG protein may play
an important role in these tissues by regulating SHP-1. In
addition, the ortholog of TFG in C. elegans, tfg-1, suppresses
apoptosis and is essential for normal cell size [4].
Recently, we produced an antibody specific to the rat
TFG protein [11]. Immunohistochemistry using the antibody
localized TFG to some neurons in restricted regions. The
distribution suggested that TFG protein could play an
important role in specific neuronal functions. To explore
this hypothesis, we mapped the distribution patterns of TFG-
positive neurons in rat brainstem, cerebellum, and spinal
cord using the TFG-specific antibody.
II. Materials and Methods
Animals
Ten male Wistar rats weighing 200–300 g at the start
of the experiment were used in this study. The rats were
purchased from Clea Japan (Osaka, Japan). All animal
experiment was performed following the PHS Policy on
Humane Care and Use of Laboratory Animals, the NIH
Guide for the Care and Use of Laboratory Animals (NIH
publication No. 85-23, revised 1985), and the Animal
Welfare Act (7 U.S.C. et seq.). The animal-use protocolTakeuchi et al. 58
was approved by the Institutional Animal Care and Use
Committee of Shiga University of Medical Science. All
animals were housed under a 12 hr:12 hr light-dark schedule.
Food and water were given ad libitum.
Tissue preparations
Ten male Wistar rats were used in this study. Tissue
preparation was performed essentially as reported before
[1, 25]. In brief, under pentobarbital anesthesia (80 mg/kg),
rats were transcardially perfused with 10 mM phosphate-
buffered saline (PBS) followed by ice-cold 0.1 M phosphate
buffer (PB; pH 7.4) containing 4% formaldehyde (FA). The
brain was removed from each rat and the spinal cord was
removed from two rats, and they were postfixed for 24 hr
in 0.1 M PB containing 4% FA at 4°C. The tissues were
then immersed for at least 48 hr in 0.1 M PB containing
15% sucrose and 0.1% sodium azide for cryoprotection. The
tissues were cut into 20-µm thick sections using a cryostat.
Sections were used in a free-floating state.
Production and characterization of antibody against TFG 
proteins
The production and characterization of the antibody to
TFG was described previously [11]. In brief, the antisera
was raised in rabbits using a synthetic peptide correspond-
ing to the common region of TFG protein and its variant
as an antigen (SGPPSAPTEDRSGTP: amino acid number
194–208, Accession number BC078947 on GenBank). This
peptide was conjugated to bovine serum albumin (BSA)
using glutaraldehyde treatment. Antisera were raised in
rabbits by immunizing with this antigenic preparation. The
best antiserum was then purified by affinity chromatography
using the antigenic peptide (SGPPSAPTEDRSGT) bound
to CNBr-activated sepharose gel.
The specificity of the antibody was assessed by western
blot analysis and immunoabsorption test. Western blotting
revealed two bands with molecular weights of approximately
30 kDa and 50 kDa in the brain homogenate, which
correspond in molecular size to the conventional and variant
forms of TFG, respectively [11].
Immunohistochemistry
Immunohistochemical staining for TFG was performed
as previously described [1, 11, 16, 17, 22, 25]. In brief, the
sections were kept at 4°C for at least 4 days in 0.1 M PBS
containing 0.3% Triton X-100 (PBST; pH 7.4) before
staining. Sections were incubated for 20 min with PBST
containing 0.3% H2O2 and 0.1% sodium azide at room
temperature to eliminate endogenous peroxidase. After
washing with PBST, sections were incubated for 30 min
with PBST containing 2% BSA to inhibit non-specific
protein binding. The sections were incubated in sequence
with the rabbit anti-TFG antiserum (1:5,000–20,000) or
the purified TFG antibody (0.1 µg/ml) at 4°C overnight,
biotinylated anti-rabbit IgG (1:1,000; Vector Laboratories,
Burlingame, CA, USA) for 1 hr at room temperature,
and the avidin-biotin-peroxidase complex (1:3,000; Vector
Laboratories) for 1 hr at room temperature. PBST containing
0.2% BSA was used to dilute the antibodies and PBST was
used to wash the sections between each step. A purple
color was developed with 0.02% 3,3'-diaminobenzidine,
0.0045% H2O2, and 0.3% nickel ammonium sulfate in 50
mM Tris–HCl buffer (pH 7.6). The free-floating sections
were mounted on gelatin-chrome-coated glass slides and
air-dried.
For the immunoabsorption test, the purified antibody
was preincubated with the TFG peptide (100 µg/mL) for 2
hr at 4°C, and the sections were then stained as described
above. All staining was abolished following preincubation
of the antibody with the TFG peptide.
Double fluorescence immunohistochemistry
The colocalization of TFG and serotonin-positive
neurons in some midbrain sections was examined using
double labeling for TFG and serotonin with fluorescence-
labeled secondary antibodies. The sections were incubated
with a mixture of the rabbit polyclonal antibody (1:5,000)
to TFG and mouse monoclonal antibody to serotonin
(1:1,000) [22] for 3 days at 4°C. The sections were incubated
for 1 hr with a mixture of Alexa 488-conjugated anti-rabbit
IgG (1:500; Molecular Probes, Eugene, OR) and Alexa 555-
conjugated anti-mouse IgG (1:500; Molecular Probes) at
room temperature. Sections were given three rinses with
PBST then mounted on silan-coated glass slides and
examined using a confocal microscope (Nikon C1si,
TE2000-E, Nikon, Tokyo, Japan). PBST containing 0.2%
BSA was used to dilute the antibodies and PBST was used
to wash the sections between each step.
Cell counting
The number of TFG- and/or serotonin-immunopositive
cells was determined in three 20-µm samples of rat mid-
brain. Confocal microscopy was used to capture images of
fluorescently-labeled neurons in the dorsal, paramedian and
median raphe nuclei at levels of –8.30, –8.00, and –7.64
mm from the Bregma [18]. The number of cells positive for
TFG, serotonin or both in these images was counted by eye.
III. Results
TFG immunoreactivity was detected in neurons of adult
rat brain. Figure 1 illustrates the distribution maps of these
TFG-positive neurons with seven schematic drawings of
coronal sections from the midbrain, pons, medulla and
cerebellum, using the atlas of Paxinos and Watson [18] as
a reference for the drawings (Fig. 1). The areas with TFG-
positive neurons were labeled with dot circles (Fig. 1).
Typical examples of TFG-positive neurons are presented in
Figures 2 and 3.
Distribution of TFG-positive neurons in the midbrain, pons, 
and medulla
The most prominent TFG immunoreactivity in the
midbrain (Fig. 1A and 1B) was observed in the mesen-TFG Proteins in the Rat Brainstem 59
cephalic trigeminal nucleus (Fig. 2A) and the raphe nuclei
(Fig. 2B and 2C). In the mesencephalic trigeminal nucleus,
large neurons with paraphytes, named by Nageotte [2, 15],
were intensely positive for TFG (Fig. 2A). In the dorsal
(Fig. 2B and 2C) and median raphe nuclei (Fig. 2D), clusters
of intensely stained neurons were observed. At a large
magnification, TFG-immunoreactivity was localized to
neuronal somata and proximal processes (Fig. 2C). In the
oculomotor nucleus, large neurons were very faintly stained
for TFG (Fig. 2E).
In the pons (Fig. 1C and 1D), densely packed, round,
small neurons were TFG-immunopositive in the pontine
nuclei (Fig. 2F). In the ventral cochlear nucleus, oval neurons
showed moderate TFG immunoreactivity (Fig. 2G). In the
nucleus of the abducens, large neurons were moderately
stained for TFG (Fig. 2H and 2I), while moderate immuno-
reactivity was observed in many medium to large-sized
neurons in the lateral vestibular nucleus (Fig. 2H and 2J).
Oval neurons in the nucleus of the trapezoid body also
showed moderate immunoreactivity (Fig. 2H and 2K). Some
positive neurons were seen in the locus coeruleus (Fig. 1C).
Although the neurons in the facial nucleus could not be
seen, neurons in the perifacial zone were intensely stained
for TFG (Fig. 2H and 2L).
In the medulla (Fig. 1E–G), motor neurons in the
ambiguus nucleus were positive for TFG (Fig. 3A). Neurons
intensely stained for TFG were scattered in the giganto-
cellular reticular nucleus (Fig. 3B). In these neurons, TFG-
immunoreactivity was mainly localized to neuronal somata
and proximal dendrites (Fig. 3B). Faint immunoreactivity
was seen in densely packed, round, small neurons in the
inferior olive (Fig. 3C). In the raphe obscurus of medulla,
immunoreactive neurons spreading along the midline were
apparent (Fig. 3D). Some neurons were positive for TFG in
Fig. 1. Mapping of TFG localization in the rat midbrain, pons, medulla and cerebellum. Schematic drawing of rat brain using the Paxinos and
Watson Altas as a reference. Br indicates Bregma and the numbers indicate distance (mm) from Bregma.
Abbreviations used in figures: 3N, oculomotor nucleus; 5N, motor trigeminal nucleus; 6N, abducens nucleus; 10N, dorsal motor nucleus of the
vagus; 12N, hypoglossal nucleus; AP, area postrema; AmbC, ambiguus nucleus, compact part; CC, central canal; DR, dorsal raphe nucleus; Gi,
gigantocellular reticular nucleus; IO, inferior olive; LC, locus coeruleus; LVe, lateral vestibular nucleus; LRt, lateral reticular nucleus; Me5,
mesencephalic trigeminal nucleus; p7, perifacial zone; Pn, pontine nuclei; ROb, raphe obscurus nucleus; RtTg, reticulotegmental nucleus of the
pons; Sol, nucleus of the solitary tract; Sp5I, spinal trigeminal nucleus, interpolar part; Tz, nucleus of the trapezoid body; VCA, ventral cochlear
nucleus, anterior part.Takeuchi et al. 60
Fig. 2. Immunohistochemical localization of TFG protein in the nuclei of midbrain (A–F) and pons (G–M) using the TFG-specific antibody. A–
F; In the midbrain, intensely stained neurons were seen in the mescenphalic nucleus of the trigeminal nerve (A) and dorsal raphe nucleus (B and
C). TFG-immunoreactivity is localized to neuronal somata and proximal processes (arrows in C). Neurons in the median raphe (D) were also
intensely stained. TFG-positive neurons were seen in the oculomotor nucleus (E), and the pontine nucleus (F). G–M; In the pons, neurons in the
ventral cochlear nucleus (G), the abducens nucleus (H and I), lateral vestibular nucleus (H and J), the nucleus of the trapezoid body (H and K),
and the perifacial zone (H and L) were positive for TFG immunoreactivity. Bars=50 µm (A and C); 100 µm (B, D–H, J–M); 200 µm (I).TFG Proteins in the Rat Brainstem 61
Fig. 3. Immunohistochemical localization of TFG protein in the nuclei of medulla (A–J), the cerebellum (L), and the upper cervical spinal cord
(K). A–J; In the medulla, TFG-positive neurons were seen in the ambiguus nucleus (A), the gigantocellular reticular nucleus (B), inferior olive
(C), the raphe obscurus nucleus (D), the spinal trigeminal nucleus (E), the lateral reticular nucleus (F), the nucleus of the solitary tract (G and
H), the dorsal motor nucleus of the vagus (G and I), and the hypoglossal nucleus (G and J). L and M; In the cerebellum, no signal was observed
following preincubation peptide absorption (M). Purkinje cells showed immunostaining for TFG (L). K; In the spinal cord, large motor neurons
in the anterior horn of the spinal cord were stained for TFG immunoreactivity (K). Bars=50 µm (A); 100 µm (B–F, H–M); 200 µm (G).Takeuchi et al. 62
the spinal trigeminal nucleus (Fig. 3E) and the lateral
reticular nucleus (Fig. 3F). Faint TFG immunostaining was
also observed in some neurons at the rim of the nucleus of
solitary tract (Fig. 3G and 3H). Neurons in the dorsal motor
nucleus of the vagus showed two different immunoreactive
intensities for TFG (Fig. 3G and 3I); those with intense
immunoreactivity for TFG were wide cells with dendrites.
TFG-positive immunoreactivity was also recognized in the
hypoglossal nucleus (Fig. 3G and 3J).
Distribution of TFG-positive neurons in the cerebellum and 
the spinal cord
In the cerebellum, Purkinje cells were clearly positive
for TFG, and were moderately stained (Fig. 3L). In the
spinal cord, large motor neurons in the anterior horn were
moderately immunostained for TFG throughout the spinal
cord including the cervical (Fig. 3K, 4A and 4B) and lumbar
spinal cord (Fig. 4C and 4D).
Pre-incubation of the antibody with a TFG peptide
removed any staining, which confirmed that the observed
staining was specific for TFG (Fig. 3M).
TFG-positive neurons partly colocalize with serotonin-
positive neurons in the dorsal raphe nucleus
The distribution pattern of TFG-positive neurons
was very similar to that of serotonin-positive neurons in
the raphe nuclei (Fig. 2B–D, and 3D). Therefore, double
immunofluorescent histochemical staining of rat midbrain
sections was employed to investigate the cellular colocal-
ization of TFG and serotonin (Fig. 5). The ratio of
colocalization varied among the raphe subnuclei (Table 1).
In the dorsal raphe nuclei, the ratio of colocalized neurons
to total neurons were 28% (Table 1), where 44% of
serotonin-positive neurons stained for TFG, and 42% of
TFG-positive neurons were positive for serotonin. In the
paramedian and median raphe nuclei, the ratios of TFG and
serotonin colocalization were only 5% and 16%, respectively
(Table 1).
IV. Discussion
The present study demonstrated localization of TFG-
positive neurons in the rat brainstem, cerebellum, and spinal
Fig. 4. Immunohistochemical localization of TFG protein in the anterior horn of the cervical (A and B), and the lumbar (C and D) spinal cord.
A and B; TFG-positive neurons seen in the anterior horn at the C3 cervical spinal cord (A). Magnified image of box in A (B). C and D;
TFG-positive neurons seen in the anterior horn at the L2 lumbar spinal cord (C). Magnified image of box in C (D). Bars=200 µm (A and C); 50
µm (B and D).
Fig. 5. Double immunostaining for TFG (green) and serotonin (red) in the dorsal raphe nucleus. A; TFG-immunoreactive neurons (A). B;
serotonin-immunoreactive neurons (B). C; Merged image of A and B (C). Bars=200 µm.TFG Proteins in the Rat Brainstem 63
cord using the antibody specific to TFG proteins. The
production and characterization of the anti-TFG antibody
were previously reported [11]. In brief, the antibody
recognizes the common region of the conventional and
variant forms of rat TFG. Western blot analysis using rat
brain homogenates showed an intense band of about 50 kDa
and a weak band of about 30 kDa, which are the expected
sizes of the conventional and variant form of TFG,
respectively. Immunohistochemical analysis of the rat brain
has identified specific TFG-positive neuronal populations
but the distribution patterns of these neurons were not
reported. In this study, we mapped TFG-positive neurons
in rat brainstem, cerebellum, and spinal cord using the TFG-
specific antibody. Knowledge of the distribution patterns of
TFG will facilitate further analyses of the functional role of
TFG in neurons.
The most conspicuous result in this study is that
neurons intensely stained for TFG were distributed in the
raphe nuclei in the brainstem. The distribution pattern of
TFG in the raphe nuclei was similar to that of serotonin
neurons. Double immunostaining for TFG and serotonin
demonstrated that TFG was localized to a subpopulation
of serotonin. In addition, some TFG-positive neurons were
negative for serotonin.
We demonstrated that TFG is mainly localized in the
cytoplasm of neurons, and shows an immunostaining
pattern consistent with a recent study that localized TFG
to endoplasmic reticulum exit sites [23]. TFG has been
suggested to play an important role in vesicle transportation
from the endoplasmic reticulum to the Golgi [23]. Interest-
ingly, we demonstrated TFG immunoreactivity in proximal
processes and varicose fibers in some neurons, suggesting
a novel function of TFG that differs from its role at the
endoplasmic reticulum. There was only weak immuno-
staining of TFG in axons and axonal terminals with the
TFG antibody we used in this study, suggesting that TFG
is probably not involved in axonal extension. Interestingly,
TFG-positive neurons were observed in specific brain
regions, and we have mapped these regions in the rat
brainstem (Fig. 1).
TFG-positive neurons were found in some cranial
nuclei-containing motor neurons, although not in all motor
neurons. Additionally, TFG immunoreactivity was found in
the anterior horn motor neurons throughout the spinal cord.
These findings indicate that TFG could play a role in motor
movement or motor coordination. The additional observation
of TFG immunoreactivity in Purkinje cells in the cerebellum
argues for a role in motor coordination. To examine the
physiological role of TFG in the nervous system, further
study using animal models will be needed.
V. Conclusion
We have mapped TFG-positive neurons in the rat
brainstem, cerebellum, and spinal cord. In the brainstem,
neurons intensely positive for TFG were distributed in the
raphe nuclei, the gigantocellular reticular nucleus, the
reticulotegmental nucleus of the pons, and some cranial
nerve nuclei such as the trigeminal nuclei, the vestibulo-
cochlear nuclei, and the vagus nerve nuclei. Purkinje cells
in the cerebellum and motor neurons in the spinal anterior
horn were also TFG-positive. The TFG immunoreactive
neurons in the raphe nuclei were colocalized to a sub-
population of serotonergic neurons. These localization data
provide the basis for further studies of the functional role
of TFG in the brain.
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